Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis

Clinica Chimica Acta

Volumn 289, Issue 1-2, 1999, Pages 99-110

  Acebes, Carlos ^a   De La Piedra, Concepción ^a   Traba, Maria Luisa ^a   Seibel, Markus J ^b   Martín, Carlos García ^c   Armas, Jacome ^d   Herrero Beaumont, Gabriel ^a  

^a Bone and Mineral Metab Laboratory   (Spain)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BIO RAD Laboratories   (Spain)

^d Hospital Santo Espirito de Angra do Heroesmo   (Portugal)

Author keywords

Ankylosing spondylitis; Bone sialoprotein; Osteopenia; Procollagen I propeptides; Pyridinolines; Telopeptides

Indexed keywords

ANALGESIC AGENT; BIOCHEMICAL MARKER; COLLAGEN DERIVATIVE; DEOXYPYRIDINOLINE; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOLLAGEN; PYRIDINOLINE; SIALOPROTEIN;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; OSTEOPENIA; PRIORITY JOURNAL; STATISTICS;

ADULT; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIALOGLYCOPROTEINS; SPONDYLITIS, ANKYLOSING;

EID: 0032720862     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00170-9     Document Type: Article

References (35)

1. Arnett FC, Chakraborty R. Ankylosing spondylitis: The dissection of a complex genetic disease. Arthritis Rheum 1997;40:1746-8.
2. Calin A. Ankylosing spondylitis. In: Kelley WN, editor, Textbook of rheumatology, Philadelphia: W.B. Saunders, 1989, pp. 1021-34.
3. Hanson CA, Shagrin JW, Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop 1971;74:59-64.
4. Will R, Palmer R, Bhalla AK, Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event. Lancet 1989;ii:1483-5.
5. Szejnfeld VL, Monier-Faugere MC, Bognar BJ, Bosi Ferrraz M, Malluche HH. Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. J Rheumatol 1997;24:683-8.
6. Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993;52:343-6.
7. Marhoffer W, Stracke H, Masoud I et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
8. Bronson WD, Walker SE, Hillman LS, Keisler D, Hoyt T, Allen SH. Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 1998;25:929-35.
9. Delmas PD. Biochemical markers of bone remodeling in osteoporosis. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD, editors, Osteoporosis, International congress series 1118, Amsterdam: Elsevier, 1996, pp. 191-204.
10. Domínguez Cabrera C, Sosa Henríquez M, Traba ML, Alvarez Villafañe E, De la Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporosis Int 1998;8:147-51.
11. Melkko J, Niemi S, Risteli L, Ristel J. Radioimmunoassay for the carboxyterminal propeptide of human type I procollagen (PICP). Clin Chem 1990;36:1328-32.
12. Seibel MJ, Robins SP, Bilezikian P. Urinary pyridinium crosslinks of collagen. Trends Endocrinol Metab 1992;3:263-70.
13. Bonde M, Qvist P, Fledelius C, Riis BJ, Christinasen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;39:635-40.
14. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
15. De la Piedra C, Traba ML, Dominguez Cabrera C, Sosa Henríquez M. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis. Clin Chim Acta 1997;265:225-34.
16. Stubbs III JT, Mintz KP, Eanes ED, Torchia DA, Fisher LW. Characterization of native and recombinant bone sialoprotein: Delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain. J Bone Miner Res 1997;12:1210-22.
17. Seibel MJ, Woitge HW, Pecherstorfer M et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996;81:3289-94.
18. Seibel MJ, Pecherstorfer M, Woitge HW et al. Serum bone sialoprotein in osteoporosis, multiple myeloma and monoclonal gammopathy of undetermined significance [abstract]. Bone 1997;20(Suppl):54S.
19. Moll JMH, Wright V. New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis 1973;32:354-63.
20. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of New York criteria. Arthritis Rheum 1984;27:361-8.
21. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, WHO Tech rep ser 843, Geneva, Switzerland: WHO, 1994.
22. Díaz Curiel M, Turbí Disla C, Rapado A, García JJ. Prevalencia de osteopenia y osteoporosis densitométrica en la población masculina española. Revista Española de Enfermedades Metabólicas Oseas 1997;6:129-32.
23. Díaz Curiel M, Carrasco de la Peña JL, Honorato Perez J, Perez Cano R, Rapado A, Ruiz Martinez I. Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Osteoporosis Int 1997;7:59-64.
24. Melkko J, Kauppila S, Niemi S et al. Immunoassay for intact aminoterminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
25. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired, reversed-phase, high-performance liquid chromatography. Ann Biochem 1988;169:197-201.
26. Karmatschek M, Woitge HW, Armbruster FP, Ziegler R, Seibel MJ. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem 1997;43:2076-82.
27. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
28. Kendall MJ, Lawrence DS, Shuttleworth GR. Haematology and biochemistry of ankylosing spondylitis. Br Med J 1973;2:235-7.
29. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of biphosphonate and oestrogen therapy on free and peptide-bound cross-links excretion. J Bone Miner Res 1995;10:641-9.
30. Robins SP, Seibel MJ, McLaren A. Collagen markers in urine in human arthritis. In: Maroudas A, Kuettner K, editors, Methods in cartilage research, London: Academic Press, 1990, pp. 348-52.
31. Robins SP. Biochemical basis for markers of bone metabolism. Osteoporosis (Jpn) 1996;4:157-67.
32. Chen J, Shapiro HS, Wrana JL, Reimers S, Heersche JNM, Sodek J. Localization of bone sialoprotein (BSP) expression to sites of mineral tissue formation in fetal rat tissue by in situ hybridisation. Matrix 1991;11:133-43.
33. Shapiro HS, Chen J, Wrana JL, Zhang Q, Blum M, Sodek J. Characterisation of porcine bone sialoprotein: primary structure and cellular expression. Matrix 1993;13:431-40.
34. Oldberg Å, Franzen A, Heinegard D, Pierschbacher M, Rouslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 1988;263:19433-6.
35. 3 potentiate bone resorption. J Biol Chem 1993;268:9901-7.